<DOC>
	<DOCNO>NCT01483144</DOCNO>
	<brief_summary>The purpose randomize , double-blind , Phase III trial determine combination eflornithine plus sulindac superior sulindac eflornithine single agent delay time first occurrence FAP-related event . This include : 1 ) FAP related disease progression indicate need excisional intervention involve colon , rectum , pouch , duodenum and/or 2 ) clinically important event include progression advance duodenal polyposis , cancer death .</brief_summary>
	<brief_title>Trial Eflornithine Plus Sulindac Patients With Familial Adenomatous Polyposis ( FAP )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Sulindac</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>Diagnosis phenotypic classical FAP disease involvement duodenum and/or colon/rectum/pouch . 1 . Genotype : APC mutation ( without family history ) require 2 . Classical FAP Phenotype : 100 's 1,000 's colorectal adenomatous polyp , usually appear teenage year UGI endoscopy/LGI endoscopy ( proctoscopy/colonoscopy ) perform within 30 day randomization . Patients intact colon/rectum , except clinical polyposis , prophylactic surgery consider stratification site . Rectal/pouch polyposis stratification site follow : 1 . At least three year since colectomy IRA/proctocolectomy pouch , demonstrate polyposis define Stage 1 , 2 , 3 , propose InSiGHT 2011 Staging System ( Appendix B ) summarize follow : Stage 1 : 1025 polyp , &lt; 5 mm Stage 2 : 1025 polyp , least one &gt; 1 cm Stage 3 : &gt; 25 polyp amenable complete removal , incompletely remove sessile polyp , evidence high grade dysplasia , even completely remove . [ Note : For stag purpose . ] 2 . For subject , rectal/pouch polyp &gt; 5 mm must excise `` baseline '' . Duodenal polyposis stratification site ; one following : 1 . Current Spigelman Stage 3 4 . ( Refer Appendix A Modified Spigelman Score Classification table ) . 2 . Prior surgical endoscopic intervention within past six month Spigelman Stage 3 4 may stag Spigelman 1 2 . Hematopoietic Status ( within 30 day prior randomization ) : 1 . No significant hematologic abnormality 2 . WBC least 3,000/mm3 3 . Platelet count least 100,000/mm3 4 . Hemoglobin least 10.0 g/dL 5 . No history clinical coagulopathy Hepatic Status ( within 30 day prior randomization ) : 1 . Bilirubin great 1.5 time ULN 2 . AST ALT great 1.5 time ULN 3 . Alkaline phosphatase great 1.5 time ULN Renal Status ( within 30 day prior randomization ) : ) Creatinine great 1.5 time ULN Hearing : ) No clinically significant hearing loss , define Section 6.2 , number 9 . If female , neither pregnant lactating . Negative pregnancy test female childbearing potential . Fertile patient must use effective contraception* . Absence gross blood stool ; red blood toilet paper acceptable . No discrete gastric duodenal ulcer great 5 mm within past year except Helicobacter pylorirelated peptic ulcer disease treat antibiotic . No invasive malignancy within past 5 year except resect nonmelanomatous skin cancer , papillary thyroid cancer , precancerous cervical dysplasia . No significant medical psychiatric problem would preclude study participation interfere capacity give inform consent . Use 81100 mg daily aspirin 700 mg aspirin week eligible . No concurrent warfarin , fluconazole , lithium , Pradaxa® direct thrombin inhibitor , Plavix® , cyclosporine , NSAIDs ( ibuprofen , aspirin , diflunisal ) , diuretic ( furosemide thiazide ) , DMSO , methotrexate , probenecid , propoxyphene hydrochloride , Tylenol® ( acetaminophen ) preparation contain aspirin cytotoxic chemotherapy drug . Willingness forego concurrent use supplement contain omega3 fatty acid , corticosteroid , nonsteroidal antiinflammatory drug FAP direct drug therapy . Able provide inform consent follow protocol requirement . Prior pelvic irradiation . Patients receive oral corticosteroid within 30 day enrollment . Treatment investigational agent prior 4 week . Use nonsteroidal antiinflammatory drug ( ibuprofen ) exceed 4 day per month , prior 6 week . Regular use aspirin excess 700 mg per week . Treatment FAP direct drug therapy ( include sulindac celecoxib , fish oil ) within 12 week study enrollment . Hypersensitivity cyclooxygenase2 inhibitor , sulfonamide , NSAIDs , salicylates ; NSAID associate symptom gastritis . Patients must cardiovascular disease risk factor define : Uncontrolled high blood pressure ( systolic blood pressure &gt; 150 mm Hg Unstable angina History document myocardial infarction cerebrovascular accident New York Heart Association Class III IV heart failure Known uncontrolled hyperlipidemia define LDLC &gt; = 190 mg/dL triglyceride &gt; = 500 mg/dL Patients significant hearing loss eligible study participation define hearing loss affect everyday life and/or hear aid require . Colon/rectum/pouch high grade dysplasia cancer biopsy large polyp ( &gt; 1 cm ) amenable complete removal . Duodenal cancer biopsy . Intraabdominal desmoid disease , stage III IV Inability provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Familial Adenomatous Polyposis</keyword>
	<keyword>Eflornithine</keyword>
	<keyword>Sulindac</keyword>
</DOC>